[#item_full_content] Cannabis list as “high-risk” product in new congressional bill; Anti-drug group pushes hemp recriminalization; DEA vs. FDA on psychedelics Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Your support makes Marijuana Moment possible… Your good deed
Read More
Federal scheduling process has “gaps” amid ongoing marijuana review (Newsletter: September 24, 2026)